0000950170-23-071474.txt : 20231219
0000950170-23-071474.hdr.sgml : 20231219
20231219160537
ACCESSION NUMBER: 0000950170-23-071474
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231216
FILED AS OF DATE: 20231219
DATE AS OF CHANGE: 20231219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanford Svai S
CENTRAL INDEX KEY: 0001591411
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40672
FILM NUMBER: 231497302
MAIL ADDRESS:
STREET 1: C/O RANI THERAPEUTICS LLC
STREET 2: 2051 RINGWOOD AVE.
CITY: SAN JOSE
STATE: CA
ZIP: 95131
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rani Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001856725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2051 RINGWOOD AVENUE
CITY: SAN JOSE
STATE: CA
ZIP: 95131
BUSINESS PHONE: (408) 457-3700
MAIL ADDRESS:
STREET 1: 2051 RINGWOOD AVENUE
CITY: SAN JOSE
STATE: CA
ZIP: 95131
4
1
ownership.xml
4
X0508
4
2023-12-16
0001856725
Rani Therapeutics Holdings, Inc.
RANI
0001591411
Sanford Svai S
2051 RINGWOOD AVE
SAN JOSE
CA
95131
false
true
false
false
Chief Financial Officer
false
Stock Option (Right to Buy)
5.44
2023-12-16
4
D
false
171500
D
2033-03-26
Class A Common Stock
171500
34300
D
Stock Option (Right to Buy)
2.84
2023-12-16
4
A
false
171500
A
2033-03-26
Class A Common Stock
171500
171500
D
Stock Option (Right to Buy)
13.21
2023-12-16
4
D
false
58334
D
2032-03-21
Class A Common Stock
58334
41666
D
Stock Option (Right to Buy)
2.84
2023-12-16
4
A
false
58334
A
2032-03-21
Class A Common Stock
58334
58334
D
Stock Option (Right to Buy)
9.44
2023-12-16
4
D
false
83724
D
2031-07-28
Class A Common Stock
83724
127788
D
Stock Option (Right to Buy)
2.84
2023-12-16
4
A
false
83724
A
2031-07-28
Class A Common Stock
83724
83724
D
The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023.
The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date.
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to
the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's
Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.
The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.
The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021.
Svai Sanford
2023-12-19